Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Adagene Inc.
ADAG | US
2.70
USD0.09
3.45%
ADAG | US
About Adagene Inc.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
2.70
Open
2.68
High
2.70
Low
2.43
Adagene Inc. a clinical stage immunotherapy company engages in the research development and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106 a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126 a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116 a human ligand-blocking anti-CTLA-4 mAb which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104 an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125 a novel anti-CSF-1R mAb which is in Phase I clinical trial; ADG206 a masked Fc engineered anti-CD137 agonistic POWERbody which is in preclinical; ADG153 a masked anti-CD47 IgG1 SAFEbody which is in preclinical stage for the treatment hematologic and solid tumors; ADG138 novel HER2xCD3 POWERbody which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152 a CD20xCD3 POWERbody which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou China.
View LessADAG | US
Risk
62.3
Sharpe
0.93
Luna's Score
51/100
Recommendation
Hold
Luna says (ADAG | US)
What's Working
Positive Momentum
Strength based on increasing price with high volume
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
56.9%1 month
62.3%3 months
104.4%6 months
93.2%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.89
Debt to equity
0.36
Debt to assets
0.20
Ent. to EBITDA
1.12
Ent. to rev.
38.99
PEG
-
Other Fundamentals
EBITDA
-36.13M
MarketCap
119.53M
MarketCap(USD)
119.53M
Div. yield
-
Op. margin
-4.53K
Erngs. growth
-
Rev. growth
-84.80
Ret. on equity
-45.70
Short ratio
0.31
Short perc.
0.09
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.59
Range1M
0.60
Range3M
1.78
Volumes: Market Activity
Rel. volume
1.04
Price X volume
78.26K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.12 | - | Expensive |
| Ent. to Revenue | 38.99 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.89 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 104.42 | - | Riskier |
| Debt to Equity | 0.36 | -1.23 | Expensive |
| Debt to Assets | 0.20 | 0.25 | Par |
| Market Cap | 119.53M | - | Emerging |
